Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

Like Bio-Hermes-001, the Bio-Hermes-002 study is setting a standard for improving participation from people who are traditionally underrepresented in Alzheimer's clinical research, with an ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

In an apparently unprecedented move, Eli Lilly is partnering with the fabled ... Vineeta Agarwala, a partner at Andreesen’s biotech arm, a16z Bio + Health, said the deal aims to combine ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and Alphabet.